Veliparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor that shows anticancer chemotherapeutic and anti-inflammatory activities. Veliparib crosses the blood-brain barrier with a 3:1 plasma:brain drug ratio. Inhibition of PARP by veliparib prevents excessive inflammation in animal models of cystic fibrosis and inhibits repair of DNA damage caused by chemotherapy or radiation in a variety of cancer models.
| Cas No. | 912444-00-9 |
|---|---|
| Purity | ≥99% |
| Formula | C13H16N4O |
| Formula Wt. | 244.29 |
| IUPAC Name | 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide |
| Synonym | ABT-888 |
| Solubility | DMSO (>15 mg/mL, or >50mM). |
| Appearance | off-white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Owonikoko TK, Zhang G, Deng X et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014 Dec;3(6):1579-94. PMID: 25124282.
Barazzuol L, Jena R, Burnet NG, et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol. 2013 Mar 19;8:65. PMID: 23510353.
Ta LE, Schmelzer JD, Bieber AJ, et al. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One. 2013;8(1):e54161. PMID: 23326593.
Anjos SM, Robert R, Waller D, et al. Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking. Front Pharmacol. 2012;3:165. PMID: 22988441.
